These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 7454090)
1. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer]. Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090 [TBL] [Abstract][Full Text] [Related]
2. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women. Klaassen DJ; Rapp EF; Hirte WE Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780 [TBL] [Abstract][Full Text] [Related]
3. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology. Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441 [TBL] [Abstract][Full Text] [Related]
4. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524 [TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer]. Yoshida M; Murai H; Miura S Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345 [TBL] [Abstract][Full Text] [Related]
6. [Phase II study of medroxyprogesterone acetate in advanced breast cancer]. Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264 [TBL] [Abstract][Full Text] [Related]
7. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer. Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173 [TBL] [Abstract][Full Text] [Related]
8. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors]. Nomura Y; Tashiro H; Hisamatsu K; Toi M Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811 [TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. Pannuti F; Longhi A; Martoni A; Piana E; Baroni M Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702 [TBL] [Abstract][Full Text] [Related]
10. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation]. Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590 [TBL] [Abstract][Full Text] [Related]
11. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results. Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227 [TBL] [Abstract][Full Text] [Related]
13. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma]. Castiglione M; Cavalli F Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153 [TBL] [Abstract][Full Text] [Related]
14. [High-dose medroxyprogesterone acetate in the treatment of metastatic carcinoma of renal parenchyma]. Popov I; Jelić S; Milanović N; Kovcin V; Vuletić Lj Srp Arh Celok Lek; 1996; 124(3-4):73-6. PubMed ID: 9102823 [TBL] [Abstract][Full Text] [Related]
15. [High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)]. Firusian N; Becher R Strahlentherapie; 1981 Dec; 157(12):808-12. PubMed ID: 7330909 [TBL] [Abstract][Full Text] [Related]
16. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer]. Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy. Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608 [TBL] [Abstract][Full Text] [Related]
18. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer]. Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869 [TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Yamashita J; Hideshima T; Shirakusa T; Ogawa M Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005 [TBL] [Abstract][Full Text] [Related]
20. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]